Cas:38832-94-9 Praseodymium D-3-heptafluorobutyrylcamphorate, 99% manufacturer & supplier

Chemical Name:Praseodymium D-3-heptafluorobutyrylcamphorate, 99%

CAS.NO:38832-94-9

Synonyms:praseodymium-hfc;MFCD00145470;Tris[3-(heptafluoropropylhydroxymethylene)-l-camphorato]praseodymium(III);Pr(hfc)3 (Praseodymium(III) tris[3-(heptafluoropropylhydroxymethylene)-l-camphorate];TRIS(3-(HEPTAFLUOROPROPYLHYDROXYMETHYLEN E)-D-CAMPHORATO)PR;PRASEODYM(III)-TRIS[3-(HEPTAFLUOROPROPYLHYDROXYMETHYLENE)-I-CAMPHORATE];TRIS[3-(HEPTAFLUOROPROPYLHYDROXYMETHYLENE)-I-CAMPHORATO]PRASEODYM(III);TRIS-3-HEPTAFLUOROPROPYL-*HYDROXYMETHYLE NE-D-CAMPHO;Tris-(3-heptafluorobutyryl-d-camphorato)-praseodym;(fluoropropylhydroxymethylene)-(+)-camphorato praseodymium

Molecular Formula:C₄₃H₄₃F₂₁O₆

Molecular Weight:1054.76000

HS Code:

Physical and Chemical Properties:

Melting point:154-157ºC

Boiling point:285.6ºC at 760mmHg

Density:N/A

Index of Refraction:

PSA:78.90000

Exact Mass:1054.27000

LogP:13.65640

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like praseodymium-hfc chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(fluoropropylhydroxymethylene)-(+)-camphorato praseodymium physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(fluoropropylhydroxymethylene)-(+)-camphorato praseodymium Use and application,MFCD00145470 technical grade,usp/ep/jp grade.

Related News: The group of diseases known as severe combined immunodeficiency, or SCID, first drew wide attention decades ago because of David Vetter, a boy born with X-linked SCID who lived in a bubble for 12 years as doctors tried to figure out how to cure him. 3-[3-chloro-N-(2-phenoxyethyl)anilino]propanenitrile manufacturers CHMP on Friday also announced that Roche pulled its Tecentriq application in triple-negative breast cancer after it noted that the EMA said the results from a late-stage trial do not favor the drug’s benefit-risk calculation in this indication. 3-amino-5-[(3-aminobenzoyl)amino]-4-methylbenzenesulfonic acid suppliers but are not expected to recover the costs of developing and marketing a treatment drug.” Due to the high costs and low demands of the drug product, it is important to efficiently use API supply during the formulation process. 5-Amino-1-(N-ethyl-2,3-O-isopropyliden-β-D-ribofuranuronamidosyl)-4-pyrazolcarboxamid vendor & factory.